Background. The main attention regarding prognostic and predictive markers in NSCLC directs towards the @entity470 -targeted pathway, where the most studied genetic alterations include @entity470 mutations, @entity470 copy number, and @entity984 mutations. We wanted to explore the prognostic impact of mutated @entity984 in the stage III setting treated with high-dose radiochemotherapy. Methods. Samples were obtained from @entity1 participating in two prospective studies of locally advanced NSCLC receiving combined radiochemotherapy: the RAKET study, a randomized phase II study where @entity1 were treated with induction chemotherapy ( @entity3003 / @entity1311 ) followed by concurrent radiochemotherapy, and the Satellite trial, a phase II study with induction chemotherapy ( @entity900 / @entity1205 ) followed by radiotherapy concurrent cetuximab. The samples were analysed regarding @entity984 mutations, @entity470 mutations, and @entity470 FISH positivity. Results. @entity1 with mutated @entity984 had a significantly inferior survival, which maintained its significance in a multivariate analysis when other possible prognostic factors were taken into account. The prevalence of @entity984 mutations, @entity470 mutations, and @entity470 FISH positivity were 28.8%, 7.5%, and 19.7%, respectively. Conclusion. Mutated @entity984 is an independent negative prognostic factor for survival in NSCLC stage III disease treated with combined radiochemotherapy. The prevalence of @entity984 mutations and @entity470 mutations are as expected in this Scandinavian population.

Mutated XXXX Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']
@entity984 :: (3845,Gene) :: ['KRAS']
